LIVE ATTENUATED MYCOPLASMA BACTERIUM, VACCINE CONTAINING IT AND METHOD FOR IDENTIFYING SUCH BACTERIUM Russian patent published in 2013 - IPC C12N1/20 A61K39/02 G01N33/569 

FIELD: medicine.

SUBSTANCE: Mycoplasma bacterium shows expression lower at least by 25% of one or more one protein specified in a group consisting of piruvate dehydrogenase, enolase, 2-desoxyribose-5-phosphataldolase and ribosomal protein L35. The vaccine containing such strain is applicable for animal vaccination against an infection caused by Mycoplasma bacteria. A method for identifying clones of such bacterium involves: placing an initial population of Mycoplasma bacterium into the attenuation environment to produce a potentially attenuated bacterial population; analysis of separate clones of the potentially attenuated bacterial population in relation to low expression of one or more said proteins; and testing the clones identified as having expression lower at least by 25% of one or more proteins in relation to virulence.

EFFECT: invention enables developing an attenuation strategy of Mycoplasma bacteria and may be used for prevention of the diseases caused by such bacterium.

16 cl, 1 dwg, 5 tbl, 3 ex